- Home
- GPCR vs ATAI Comparison
GPCR vs ATAI Comparison
Compare GPCR & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GPCR | ATAI |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 2023 | 2025 |
Fundamental Metrics
Financial Performance| Metric | GPCR | ATAI |
|---|---|---|
| Price | $48.15 | $7.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $103.17 | $15.88 |
| AVG Volume (30 Days) | 535.1K | ★ 18.5M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $4,089,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 1227.60 |
| 52 Week Low | $15.80 | $3.27 |
| 52 Week High | $94.90 | $7.22 |
Technical Indicators
Market Signals| Indicator | GPCR | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 73.26 |
| Support Level | $43.76 | $3.47 |
| Resistance Level | $57.15 | N/A |
| Average True Range (ATR) | 2.67 | 0.15 |
| MACD | -0.58 | 0.00 |
| Stochastic Oscillator | 28.59 | 98.67 |
Price Performance
Historical ComparisonAbout GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.